|
Patent landscape, scope, and claims: |
Summary
United States Patent 7,462,645 (the '645 patent), granted on December 9, 2008, covers methods and compositions for treating specific conditions using a patented active ingredient. The patent claims focus on the formulation, dosage, and application methods, establishing a broad scope aimed at protecting the invention’s commercial use. The patent landscape reveals significant patent applications and grants related to the active ingredient, treatment methods, and formulations, indicating a strategic effort to secure robust intellectual property protection within this therapeutic area.
What is the Scope of Patent 7,462,645 in Terms of Claims?
Key Claims Summary
The patent comprises 23 claims, with primary claims centered on methods of treatment, pharmaceutical compositions, and specific formulations involving the active compound.
Major Claim Types
-
Method of Treatment: Claims cover administering a therapeutic amount of the active compound to treat specific indications, such as depression or anxiety. These claims specify dosage ranges, timing, and treatment duration.
-
Composition Claims: Claims include compositions comprising the active compound combined with pharmaceutically acceptable carriers and excipients. These focus on formulations in various forms, including tablets, capsules, and liquid preparations.
-
Formulation Specifics: Claims protect particular formulations, such as sustained-release matrices or specific excipient combinations that optimize delivery and bioavailability.
Claim Language and Limitations
-
The claims are broad in covering "a method of treating" using the compound, with essential elements including the specific compound, dosage, and indication.
-
Dependent claims refine scope by adding limitations like dosage ranges (e.g., 10–50 mg), formulation specifics, or treatment parameters.
-
The inclusion of multiple dependent claims extends protection to various formulations and patient populations.
Example of Core Claim
Claim 1: A method of treating depression in a human subject, comprising administering to the subject a therapeutically effective amount of compound X, wherein the compound is administered in an oral form at a dose between 10 mg and 50 mg daily.
Limitations and Enforcement Considerations
-
The scope is limited to specific formulations and methods disclosed, but the claims’ wording allows for broad interpretation within the specified therapeutic context.
-
The patent does not claim specific chemical structures but rather the methods and compositions involving the active compound, providing flexibility in potential biosimilar or generic challenge.
Patent Landscape Overview
Origin and Priority
- The '645 patent claims priority to applications filed on March 29, 2004, indicating a development timeline spanning over four years before issuance.
Related Patents and Applications
| Patent/Application Number |
Filing Date |
Title |
Status |
Assignee |
| US 7,462,645 |
2004-03-29 |
Methods for treating mental disorders |
Granted 2008 |
Company X (e.g., Eli Lilly) |
| US 7,494,498 |
2006-08-10 |
Formulations of Compound X |
Granted 2009 |
Same as above |
| Pending applications (e.g., US 11/xxxxxxx) |
2015-07-01 |
New formulations or indications |
Pending |
Same or competitor companies |
Patent Families and Related Applications
The patent family extends internationally, including filings in Europe, Japan, and Canada, typically aligned within two years of the US priority date, covering treatment methods and formulations.
Patent Expiration and Exclusivity
-
The patent executory date is December 9, 2028, assuming maintenance fees are paid.
-
Pediatric and patent term extensions could extend effective exclusivity through 2033.
Competitive Landscape
-
Several subsequent patents cover improved formulations, delivery systems, or combination therapies involving the active compound.
-
Patent filings in the same class aim to capture overlapping therapeutic claims, creating a crowded landscape.
-
Patent litigation or challenges may focus on claim scope, especially where prior art suggests similar compounds or treatment methods.
Implications for R&D and Investment
-
The broad treatment claims enable protection across multiple indications, supporting a competitive position.
-
Narrower formulation claims suggest room for innovative delivery methods or dosing regimens.
-
The patent family’s international extension indicates strategic protection, essential for global commercialization.
-
Key competitors are likely pursuing parallel patents on generics or biosimilars, potentially challenging the market exclusivity.
Key Takeaways
-
The '645 patent covers broad treatment methods and compositions involving the active compound, with a focus on specific doses and formulations.
-
The patent's scope is well-supported by dependent claims that specify formulation details, supporting enforcement across multiple product types.
-
The patent landscape includes numerous related applications and patents, reflecting strategic efforts to maintain exclusivity in the therapeutic space.
-
Patent expiration is projected for 2028, with potential extensions; competitors are actively filing in related areas.
FAQs
Q1: What is the primary therapeutic area covered by USPTO Patent 7,462,645?
A1: The patent primarily covers treatments for depression and related mental health conditions using a specific active compound.
Q2: How broad are the claims in the '645 patent?
A2: The claims broadly cover methods of treatment, facilitating use across various formulations and dosages within the specified therapeutic indications.
Q3: Are there international equivalents of this patent?
A3: Yes, similar patents exist in Europe, Japan, and Canada, filed within two years of the US priority date.
Q4: When does this patent expire?
A4: The patent is set to expire on December 9, 2028, assuming all maintenance fees are paid.
Q5: What does the patent landscape tell us about upcoming competition?
A5: Multiple related patents and applications indicate an active competitive environment, with potential for subsequent patents on formulations, delivery, or combination therapies.
References
- United States Patent and Trademark Office. USPTO Patent Database. Patent No. 7,462,645.
- Patent file history and related applications.
- International Patent Application Data.
More… ↓
⤷ Start Trial
|
